Funding for this research was provided by:
Prinses Beatrix Spierfonds (WAR 08-24; WAR 13-07; WAR 14-26)
Stichting Spieren voor Spieren (n/a)
Received: 13 January 2020
Accepted: 24 March 2020
First Online: 10 April 2020
Ethics approval and consent to participate
: This study was approved by the Medical Ethics Committee of the University Medical Centre Utrecht (No. 09–307/NL29692.041.09). Written informed consent was obtained from all participants and/or their parents in case of minors.
: Not applicable.
: C.A.W., E.S.V., R.P.A.v.E., M.S., L.A.M.O., F.A., R.M.W.v.A., E.H.J.H., L.P.V.v.d.O, I.C., R.I.W., and W.L.v.d.P. declare no relevant financial or other conflicts of interest. B.B. receives research support from the Prinses Beatrix Spierfonds and Stichting Spieren voor Spieren. His employer receives fees for consultancy services to Cytokinetics and Scholar Rock. K.v.d.E. receives research grants from GSK, Nutricia, TEVA, Gilead, Vertex, ProQR, Proteostasis, and Galapagos, all unrelated to the submitted work. L.H.v.d.B. serves on scientific advisory boards for the Prinses Beatrix Spierfonds, Thierry Latran Foundation, Biogen Idec, and Cytokinetics; has received an educational grant from Baxter International Inc.; serves on the editorial board of Amyotrophic Lateral Sclerosis and Journal of Neurology, Neurosurgery and Psychiatry; and received research support from the Prinses Beatrix Spierfonds, Netherlands ALS Foundation, The European Community’s Health Seventh Framework Programme (grant agreement no. 259867) and The Netherlands Organization for Health Research and Development [Vici Scheme, JPND (SOPHIA, STRENGTH)], all unrelated to the submitted work.